Chinese Language Podcast: Biokin/BMS Deal, Developments At Pfizer, BlissBio, WuXi Biologics

Chinese antibody-drug conjugate developers are making further inroads in global biotech dealmaking, with Chengdu-based Biokine Therapeutics Ltd.’s US subsidiary recently inking a megadeal with Bristol Myers Squibb Company worth up to $8.4bn in total.

On 5 December, Hong Kong-listed WuXi Biologics saw a single-day share price plunge of over 23%, following a business update that revealed a broad set of challenges facing the overall Chinese biotech sector. What are the reasons, what will the impact be on the Chinese biotech sector as a whole and what is the outlook like for WuXi in 2024? 

In other developments, Brian and Dexter look at why Pfizer Inc. decided to divest commercial rights to its most popular vaccine in China, Prevenar 13, to Shanghai Pharma subsidiary Ke Yuan, and what this might mean for multinational vaccine manufacturers operating in China.  

Finally, BlissBio recently disclosed Phase I data for its ADC BB-1707 - what are the key takeaways? 

最近国内生物药企在ADC药物开发方面继续保持热度。比如BMS和百利天恒在周二宣布达成总金额84亿美元的EGFR/HER3双抗ADC的授权合作，打破了国内创新药单个出海的金额纪录。这一次合作有何深层次的信息? BL-B01D1已经在美国入组1期临床的肺癌患者。在全球处于怎样的临床竞争环境？

12月5日，香港上市公司药明生物单日股价跌幅超过23%。突如其来的暴跌表明，整个中国生物技术行业面临着一系列广泛的挑战。为什么药明生物药大幅下滑的原因，对整个中国生物科技行业有何影响？药明生物对2024年的预测是什么？

辉瑞决定将其最受欢迎的疫苗Prevenar 13的营销权出售给上海制药子公司科源。辉瑞为何将Prevenar商业化权利转让给中国的合作伙伴？ 这对中国的跨国疫苗制造商意味着什么？

此外，百力司康在今年的SABCS会议上首次报告了BB-1701在HER2低表达乳腺癌患者中的临床1期队列拓展数据。其中有哪些值得关注的地方（比如艾力布林毒素）？  国内其他创新药企在HER2低表达乳腺癌这一适应症上有更多研发进展吗？

直播中提及的文章链接如下：

(Also see "BMS Bets $8.4bn On Biokin’s Bispecific ADC" - Scrip, 12 Dec, 2023.)

(Also see "Bellwether Wuxi Biologics' Plunge Indicative Of China Biotech Challenges" - Scrip, 6 Dec, 2023.)

(Also see "Pfizer Divests Select China Prevenar 13 Rights, Staff As Domestic Firms Gain Traction" - Scrip, 28 Nov, 2023.)

(Also see "New Results Provide Glimpse Into BlissBio's Enhertu Challenger In HER2-Low Breast Cancer" - Scrip, 11 Dec, 2023.)